Oxytrol: Overactive Bladder Relief with Transdermal Delivery
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.40 | $42.14 (0%) | 🛒 Add to cart |
| 60 | $1.22 | $84.28 $73.10 (13%) | 🛒 Add to cart |
| 90 | $1.15 | $126.42 $103.20 (18%) | 🛒 Add to cart |
| 120 | $1.12 | $168.56 $134.16 (20%) | 🛒 Add to cart |
| 180 | $1.08 | $252.84 $194.36 (23%) | 🛒 Add to cart |
| 270 | $1.05 | $379.26 $284.66 (25%) | 🛒 Add to cart |
| 360 | $1.05
Best per pill | $505.68 $376.68 (26%) | 🛒 Add to cart |
Synonyms
| |||
Oxytrol (oxybutynin transdermal system) is a prescription medication designed for the management of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency. Utilizing a unique transdermal delivery system, it provides continuous release of oxybutynin, a muscarinic antagonist, through the skin directly into the systemic circulation. This method offers a favorable pharmacokinetic profile, bypassing first-pass metabolism and potentially reducing certain anticholinergic side effects commonly associated with oral formulations. It is indicated for adults seeking a non-oral alternative for OAB symptom control, combining efficacy with patient convenience.
Features
- Transdermal delivery system for continuous 96-hour drug release
- Contains oxybutynin, an antimuscarinic agent
- Available in 3.9 mg/day system
- Water-resistant adhesive backing
- Each system is sealed in a polyethylene-lined polyester release liner
- Applied to dry, intact skin on abdomen, hip, or buttock
Benefits
- Provides steady-state plasma concentrations for consistent symptom control over 3-4 days
- Reduces episodes of urge incontinence and urinary frequency
- Minimizes first-pass hepatic metabolism, potentially lowering metabolite-related side effects
- Offers dosing convenience with twice-weekly application
- Avoids gastrointestinal variability in drug absorption
- May result in fewer anticholinergic effects like dry mouth compared to some oral anticholinergics
Common use
Oxytrol is primarily prescribed for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. It is used in adults who require pharmacological intervention beyond behavioral modifications. The transdermal system is particularly suitable for patients who experience difficulty with oral medication adherence or who develop significant adverse effects from oral anticholinergic agents. Some clinicians may consider it for neurogenic bladder management in specific cases, though this constitutes off-label use.
Dosage and direction
Apply one Oxytrol system to dry, intact skin on the abdomen, hip, or buttock twice weekly (every 3-4 days). The application site should be rotated, with no repeat application to the same site within 7 days. Ensure the skin is clean, dry, and free of oils, lotions, or powders before application. Press firmly in place for 30 seconds to ensure proper adhesion. Replace the system on a regular schedule (e.g., every Sunday and Wednesday). Do not cut the system. If partial detachment occurs, reapply to a different site if necessary or replace if inadequate adhesion persists.
Precautions
Avoid exposure of application site to external heat sources (e.g., heating pads, prolonged direct sunlight) as this may increase drug absorption. Monitor for signs of urinary retention in patients with bladder outlet obstruction. Use with caution in patients with gastrointestinal obstructive disorders due to decreased motility. May cause drowsiness or blurred vision; patients should exercise caution when driving or operating machinery until effects are known. Elderly patients may be more sensitive to anticholinergic effects. Not recommended for patients with hepatic impairment. Skin reactions may occur at application site; rotate sites and monitor for dermatitis.
Contraindications
Patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. Those with known hypersensitivity to oxybutynin or any component of the transdermal system. Patients with myasthenia gravis or severe ulcerative colitis. Contraindicated in patients with toxic megacolon or intestinal atony.
Possible side effects
Most common: application site reactions (pruritus, erythema, rash), dry mouth, constipation. Less common: dizziness, somnolence, blurred vision, urinary retention, gastrointestinal discomfort, diarrhea, dry eyes. Rare: angioedema, tachycardia, hallucinations, cognitive effects in elderly patients. Discontinuation rates due to application site reactions are approximately 5-10%. Systemic anticholinergic effects are generally less frequent than with immediate-release oral formulations but may still occur.
Drug interaction
May potentiate effects of other anticholinergic drugs. Concurrent use with CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin) may increase oxybutynin concentrations. May reduce efficacy of metoclopramide and other prokinetic agents. May enhance sedative effects when combined with CNS depressants (benzodiazepines, opioids). Use cautiously with other drugs that cause constipation. Monitor for increased anticholinergic effects when administered with tricyclic antidepressants or antipsychotics.
Missed dose
Apply the next system as soon as remembered, then resume the regular twice-weekly schedule. Do not apply two systems simultaneously to make up for a missed dose. If more than one day has passed since the missed dose, consider the missed system skipped and continue with the regular schedule.
Overdose
Symptoms may include severe anticholinergic effects: central nervous system excitation (restlessness, tremor, irritability), hallucinations, severe dry mouth, blurred vision, urinary retention, tachycardia, hyperthermia, seizures, or cardiovascular collapse. Treatment is supportive and symptomatic. Activated charcoal may be considered if oral ingestion of system contents occurs. ECG monitoring recommended for cardiac effects. Physostigmine may be considered for severe central anticholinergic effects in hospital settings.
Storage
Store at 20-25°C (68-77°F). Excursions permitted between 15-30°C (59-86°F). Keep in original pouch until time of use. Do not freeze. Keep out of reach of children and pets. Used systems should be folded with adhesive sides together and disposed of properly to prevent accidental application or ingestion.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Oxytrol is a prescription medication that should be used only under the supervision of a qualified healthcare provider. Patients should not initiate, discontinue, or change dosage without medical consultation. Individual results may vary based on patient factors and disease state. The full prescribing information should be consulted before use.
Reviews
Clinical studies demonstrate Oxytrol provides significant reduction in weekly incontinence episodes (median 66-75% reduction) and urinary frequency compared to placebo. Patient-reported outcomes show improvement in quality of life measures. Dermatological reactions are the most frequently reported adverse event, leading to discontinuation in some patients. Many patients appreciate the convenience of twice-weekly dosing compared to daily oral medications. Long-term studies support maintained efficacy over 6 months of treatment with consistent safety profile.